Sugi Predict

Sugi Predict / Compounds / SCHEMBL12566554

SCHEMBL12566554

SCHEMBL12566554

CCN1CCN(CC)C(=O)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ POLB P06746 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ F2 P00734 1/20 0.38
▸ ELANE P08246 1/20 0.38
▸ CTSG P08311 1/20 0.38
▸ CTRC Q99895 1/20 0.38
▸ HTT P42858 2/20 0.36
▸ INMT O95050 2/20 0.35
▸ MAPT P10636 2/20 0.33
▸ GMNN O75496 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ THPO P40225 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ PMP22 Q01453 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ MGLL Q99685 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148826 0.87 GAA (0.46) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL7145277 0.87 GAA (0.42) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL12208453 0.87 GAA (0.42) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL7139392 0.87 GAA (0.42) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL12709502 0.87 GAA (0.42) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL10967106 0.87 GAA (0.42) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL28533846 0.85 GAA (0.41) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL10964562 0.83 GAA (0.40) GAAL3MBTL1POLBSMN1; SMN2ALOX15
SCHEMBL12545892 0.83 PIK3CD (0.48) GAAL3MBTL1POLBSMN1; SMN2P2RX7
SCHEMBL11759308 0.82 POLB (0.40) GAAL3MBTL1POLBSMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633206-B2 Pyrrolo[2,3-D]pyrimidine compounds PFIZER INC. (US) 2014-01-21 — — US disclosed
EP-2488524-B1 PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS PFIZER (US) 2013-07-03 — — EP disclosed
US-20110136765-A1 Pyrrolo[2,3-D]Pyrimidine Compounds PFIZER INC. (US) 2011-06-09 — — US disclosed
WO-2011045702-A1 PYRROLO[2,3-D] PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2011-04-21 — — WO disclosed
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors BLANCO MIGUEL GARCIA-GUZMAN 2009-09-24 — — US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 GAA 3977/4885L3MBTL1 4377/4885POLB 4438/4885
US-20110136765-A1 Pyrrolo[2,3-D]Pyrimidine Compounds JAK3, JAK1, JAK2 GAA 3441/4885L3MBTL1 4483/4885POLB 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.